The Herz P1 is positioned as a standalone fingertip pulse oximeter built for daily home monitoring. The company's marketing focuses on adults managing COPD, heart conditions, post-surgery recovery, ...

PLN-101095 was generally well tolerated across all doses evaluated with few discontinuations (n=2) due to adverse events. Rash was the most common treatment-related adverse event (TRAE), all Grade 1 ...

Ismail L. Ali, J.D., Co-Executive Director, MAPS As federal agencies are directed to reduce barriers to clinical research and accelerate drug approvals for psychedelic substances, it is critical that ...

ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study. First head-to-head, double-blind, randomized phase 4 study powered to ...

ADAPT SERON, OCULUS, and Jr study results build on VYVGART's approved gMG indication and show its potential as the first and only biologic therapy effective across MG subtypes ADHERE post hoc analysis ...

References to benefits, side effects risk, and customer complaints reflect commonly searched consumer questions and are included to address public interest topics in a clear, informational manner.

The phrase "claims evaluated" in this context refers only to research of how product information is presented across the official Steel Flow Pro pages and label disclosures. It does not mean the ...

A 2026 structured overview of VidaCalm's 18-ingredient hearing support formula, ingredient research context, safety considerations, and what consumers searching for tinnitus relief should verify ...

In preclinical studies including patient-derived tumor xenograft models, PHST001 enhanced macrophage-mediated tumor control and prolonged survival in combination with chemotherapies and antibody-drug ...

Revolution Medicines Announces Closing of Concurrent Upsized Public Offerings with Aggregate Gross Proceeds of Approximately $2.2 Billion, Including Full Exercise of Underwriters’ Option to Purchase ...

Following the presentation on April 19, 2026 from 2:00–5:00 PM PT, the poster titled “PLK1 inhibitor onvansertib potentiates the antitumor efficacy of trastuzumab deruxtecan (T-DXd) and reverses its ...

ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer ...